Finland In-Vitro Diagnostics Market Size and Share

Name: Finland In-Vitro Diagnostics Market Size and Share | 2024-2030
Creator: Supradip Baul
Published: Sep 2025

Download Now

Finland In-Vitro Diagnostic Market by Product & Service (Reagents & Consumables, Instruments & Devices, and Software & Services), by Technique (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology & Coagulation, and Other), by Testing Site / Channel (Central & Reference Laboratories, Hospital & Physician Labs, and Others), by Application / Disease Area (Infectious Diseases, Oncology, Cardiovascular Health, and Others)– Opportunity Analysis and Industry Forecast, 2024–2030.

Download PDF

Speak to Our Analyst

Finland In-Vitro Diagnostics Market Overview

The Finland In-Vitro Diagnostics Market size was valued at USD 440.38 million in 2023, and is predicted to reach USD 686.92 million by 2030, at a CAGR of 6.1% from 2024 to 2030. In-Vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, in-vitro experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Growing Burden of Chronic Diseases in Finland Fuels IVD Market Growth

Finland’s in-vitro diagnostics market is expanding as chronic diseases place increasing pressure on the national healthcare system. Cardiovascular disorders, cancers, diabetes, and neurodegenerative diseases remain the leading causes of morbidity and mortality, driving the need for advanced diagnostic capabilities. These conditions require frequent monitoring and timely detection, thereby strengthening reliance on laboratory testing and molecular assays.

National screening programs and preventive healthcare policies further stimulate demand for IVD solutions. Large-scale initiatives for cancer screening, cardiovascular risk assessment, and dementia management emphasize the use of precise diagnostic tools. The growing elderly population, combined with the government’s focus on early detection, ensures that demand for high-quality diagnostics will remain a structural driver of market growth.

Strong Medical Equipment Industry Strengthens Finland’s IVD Market

Finland’s position as a leader in health technology exports provides a strong industrial foundation for the IVD market. Medical equipment, including diagnostic instruments, constitutes the largest share of the country’s health technology exports, reflecting both advanced manufacturing capabilities and global competitiveness. This strong industrial base underpins innovation and ensures availability of high-quality diagnostic tools for domestic use.

The prominence of medical technology within Finland’s export portfolio also supports domestic adoption of in-vitro diagnostics. The ecosystem of research organizations, healthcare providers, and technology manufacturers enables faster development and integration of diagnostic solutions. This alignment between industrial strength and healthcare demand creates an environment where IVD technologies can scale efficiently.

High R&D and Regulatory Costs Constrain Market Expansion

Despite growth potential, high costs of research, product development, and regulatory approvals continue to restrain the IVD market in Finland. Developing reliable diagnostic assays requires significant investment in clinical validation, laboratory trials, and technology refinement. These upfront costs create barriers for smaller companies and delay time-to-market for innovative solutions.

Regulatory compliance further adds to the financial burden. Stringent European standards and national approval requirements demand robust evidence of safety and efficacy, extending development timelines and costs. While these regulations ensure quality and patient safety, they also limit the pace at which new technologies can be introduced and commercialized in Finland.

Opportunities in Point-of-Care Testing Accelerate Market Growth

Point-of-care testing (POCT) is emerging as a key growth opportunity within Finland’s IVD market. These decentralized diagnostic tools allow healthcare professionals to conduct rapid testing in primary care centers, pharmacies, and emergency units, reducing reliance on centralized laboratories. POCT solutions provide immediate results for infectious diseases, cardiac biomarkers, and metabolic conditions, enabling faster treatment decisions.

The integration of POCT with digital health records and telehealth services strengthens diagnostic efficiency and accessibility. By complementing centralized laboratory systems, point-of-care testing enhances patient-centered care, particularly in rural and underserved regions. This hybrid model of laboratory and decentralized diagnostics is expected to define the next phase of Finland’s IVD market expansion.

Competitive Landscape

The promising players operating in the Finland in-vitro diagnostics industry include Roche Diagnostics Oy, Abbott Oy, Siemens Healthineers, Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific, Becton, Dickinson and Company, Sysmex Corporation, bioMérieux, Bio-Rad Laboratories, QuidelOrtho Corporation, Qiagen, Hologic, Inc., Diasorin S.p.A., Grifols Nordic AB, Aidian Oy, and others.

Finland In-Vitro Diagnostic Market Key Segments

By Product & Service

Reagents & Consumables
- Clinical Chemistry Reagents
- Immunoassay Reagents (ELISA/CLIA)
- Molecular Master Mixes
- Hematology Controls
Instruments & Devices
- Chemistry Analyzers
- Immunoassay Systems
- Molecular Thermocyclers/Sequencers
- Hematology Analyzers
- POC Devices
Software & Services
- LIS, Data Analytics
- CRO/Testing Services

By Technique

Clinical Chemistry
- Metabolites
- Electrolytes
- Enzymes
Immunoassays
- ELISA / CLIA / CMIA
- Lateral-flow Rapid Tests
- Immunofluorescence
Molecular Diagnostics
- PCR
- Isothermal NAAT
- NGS
- In-situ Hybridization
Hematology & Coagulation
- CBC Analyzers
- Coagulation Panels
Microbiology
- Culture & Sensitivity
- MALDI-TOF
- Molecular ID
Urinalysis & Body Fluids
Other Techniques

By Testing Site / Channel

Central & Reference Laboratories
Hospital & Physician Labs
Point-of-Care & Retail
Home & Self-Testing

By Application / Disease Area

Infectious Diseases
Oncology
Cardiovascular Health
Endocrinology & Diabetes
Nephrology
Genetic & Prenatal Testing
Autoimmune Disorders
Drug Monitoring & Toxicology
Blood Screening & Typing
Other Indications

Key Players

Roche Diagnostics Oy
Abbott Oy
Siemens Healthineers
Danaher Corporation (Beckman Coulter)
Thermo Fisher Scientific
Becton, Dickinson and Company
Sysmex Corporation
bioMérieux
Bio-Rad Laboratories
QuidelOrtho Corporation
Qiagen
Hologic, Inc.
Diasorin S.p.A.
Grifols Nordic AB
Aidian Oy

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Market Size Value in 2023	USD 440.38 million
Revenue Forecast in 2030	USD 686.92 million
Value Growth Rate	CAGR of 6.1% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Million (USD)
Growth Factors	Growing Burden of Chronic Diseases in Finland Fuels IVD Market Growth Strong Medical Equipment Industry Strengthens Finland’s IVD Market
Companies Profiled	15
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

1. 1.1. REPORT DESCRIPTION
2. 1.2. WHO SHOULD READ THIS REPORT
3. 1.3. KEY MARKET SEGMENTS
4. 1.4. RESEARCH METHODOLOGY
5. 1. 1.4.1 MARKET SIZE ESTIMATION METHODOLOGY
  2. 1. 1.4.1.1. TOP-DOWN AND BOTTOM-UP APPROACH
    2. 1.4.1.2. DEMAND AND SUPPLY-SIDE ANALYSIS
    3. 1.4.1.3. MACRO-INDICATOR APPROACH
  3. 1.4.2 DATA COLLECTION APPROACH
  4. 1. 1.4.2.1. PRIMARY DATA COLLECTION
    2. 1.4.2.2. SECONDARY DATA COLLECTION
  5. 1.4.3 SECONDARY DATA SOURCES
  6. 1.4.4 FORECASTING

1. 2.1. DEFINITION
2. 2.2. SCOPE

1. 3.1. MARKET SNAPSHOT, 2024 - 2030, MILLION USD

1. 4.1. MARKET DYNAMICS
2. 1. 4.1.1 DRIVERS
  2. 1. 4.1.1.1. GROWING BURDEN OF CHRONIC DISEASES IN FINLAND FUELS IVD MARKET GROWTH
    2. 4.1.1.2. STRONG MEDICAL EQUIPMENT INDUSTRY STRENGTHENS FINLAND’S IVD MARKET
  3. 4.1.2 RESTRAINTS
  4. 1. 4.1.2.1. HIGH R&D AND REGULATORY COSTS CONSTRAIN MARKET EXPANSION
  5. 4.1.3 OPPORTUNITIES
  6. 1. 4.1.3.1. OPPORTUNITIES IN POINT-OF-CARE TESTING ACCELERATE MARKET GROWTH

1. 5.1. MARKET SHARE ANALYSIS OF TOP 10 FINLAND IN-VITRO DIAGNOSTICS PROVIDERS, 2024

1. 6.1 OVERVIEW
2. 6.2 REAGENTS & CONSUMABLES MARKET
3. 1. 6.2.1 CLINICAL CHEMISTRY REAGENTS
  2. 6.2.2 IMMUNOASSAY REAGENTS (ELISA/CLIA)
  3. 6.2.3 MOLECULAR MASTER MIXES
  4. 6.2.4 HEMATOLOGY CONTROLS
4. 6.3 INSTRUMENTS AND DEVICES MARKET
5. 1. 6.3.1 CHEMISTRY ANALYZERS
  2. 6.3.2 IMMUNOASSAY SYSTEMS
  3. 6.3.3 MOLECULAR THERMOCYCLERS/SEQUENCERS
  4. 6.3.4 HEMATOLOGY ANALYZERS
  5. 6.3.5 POC DEVICES
6. 6.4 SOFTWARE AND SERVICES MARKET
7. 1. 6.4.1 LIS, DATA ANALYTICS
  2. 6.4.2 CRO/TESTING SERVICES

1. 7.1 OVERVIEW
2. 7.2 CLINICAL CHEMISTRY MARKET
3. 1. 7.2.1 METABOLITES
  2. 7.2.2 ELECTROLYTES
  3. 7.2.3 ENZYMES
4. 7.3 IMMUNOASSAYS MARKET
5. 1. 7.3.1 ELISA/CLIA/CMIA
  2. 7.3.2 LATERAL-FLOW RAPID TESTS
  3. 7.3.3 IMMUNOFLUORESCENCE
6. 7.4 MOLECULAR DIAGNOSTICS MARKET
7. 1. 7.4.1 PCR
  2. 7.4.2 ISOTHERMAL NAAT
  3. 7.4.3 NGS
  4. 7.4.4 IN-SITU HYBRIDIZATION
8. 7.5 HEMATOLOGY & COAGULATION MARKET
9. 1. 7.5.1 CBC ANALYZERS
  2. 7.5.2 COAGULATION PANELS
10. 7.6 MICROBIOLOGY MARKET
11. 1. 7.6.1 CULTURE & SENSITIVITY
  2. 7.6.2 MALDI-TOF
  3. 7.6.3 MOLECULAR ID
12. 7.7 URINALYSIS AND BODY FLUIDS MARKET
13. 7.8 OTHER TECHNIQUES MARKET

1. 8.1 OVERVIEW
2. 8.2 CENTRAL AND REFERENCE LABORATORIES MARKET
3. 8.3 HOSPITAL AND PHYSICIAN LABS MARKET
4. 8.4 POINT-OF-CARE AND RETAIL MARKET
5. 8.5 HOME AND SELF-TESTING MARKET

1. 9.1 OVERVIEW
2. 9.2 INFECTIOUS DISEASES MARKET
3. 9.3 ONCOLOGY MARKET
4. 9.4 CARDIOVASCULAR HEALTH MARKET
5. 9.5 ENDOCRINOLOGY AND DIABETES MARKET
6. 9.6 NEPHROLOGY MARKET
7. 9.7 GENETIC AND PRENATAL TESTING MARKET
8. 9.8 AUTOIMMUNE DISORDERS MARKET
9. 9.9 DRUG MONITORING AND TOXICOLOGY MARKET
10. 9.10 BLOOD SCREENING AND TYPING MARKET
11. 9.11 OTHER INDICATIONS MARKET

1. 10.1 ROCHE DIAGNOSTICS OY
2. 1. 10.1.1 COMPANY OVERVIEW
  2. 10.1.2 COMPANY SNAPSHOT
  3. 10.1.3 OPERATING BUSINESS SEGMENTS
  4. 10.1.4 PRODUCT PORTFOLIO
  5. 10.1.5 BUSINESS PERFORMANCE
  6. 10.1.6 BUSINESS SEGMENTS
  7. 10.1.7 GEOGRAPHIC SEGMENTS
  8. 10.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.1.9 PRIMARY MARKET COMPETITORS
3. 10.2 ABBOTT OY
4. 1. 10.2.1 COMPANY OVERVIEW
  2. 10.2.2 COMPANY SNAPSHOT
  3. 10.2.3 OPERATING BUSINESS SEGMENTS
  4. 10.2.4 PRODUCT PORTFOLIO
  5. 10.2.5 BUSINESS PERFORMANCE
  6. 10.2.6 BUSINESS SEGMENTS
  7. 10.2.7 GEOGRAPHIC SEGMENTS
  8. 10.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.2.9 PRIMARY MARKET COMPETITORS
5. 10.3 SIEMENS HEALTHINEERS
6. 1. 10.3.1 COMPANY OVERVIEW
  2. 10.3.2 COMPANY SNAPSHOT
  3. 10.3.3 OPERATING BUSINESS SEGMENTS
  4. 10.3.4 PRODUCT PORTFOLIO
  5. 10.3.5 BUSINESS PERFORMANCE
  6. 10.3.6 BUSINESS SEGMENTS
  7. 10.3.7 GEOGRAPHIC SEGMENTS
  8. 10.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.3.9 PRIMARY MARKET COMPETITORS
7. 10.4 DANAHER CORPORATION (BECKMAN COULTER)
8. 1. 10.4.1 COMPANY OVERVIEW
  2. 10.4.2 COMPANY SNAPSHOT
  3. 10.4.3 OPERATING BUSINESS SEGMENTS
  4. 10.4.4 PRODUCT PORTFOLIO
  5. 10.4.5 BUSINESS PERFORMANCE
  6. 10.4.6 BUSINESS SEGMENTS
  7. 10.4.7 GEOGRAPHIC SEGMENTS
  8. 10.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.4.9 PRIMARY MARKET COMPETITORS
9. 10.5 THERMO FISHER SCIENTIFIC
10. 1. 10.5.1 COMPANY OVERVIEW
  2. 10.5.2 COMPANY SNAPSHOT
  3. 10.5.3 OPERATING BUSINESS SEGMENTS
  4. 10.5.4 PRODUCT PORTFOLIO
  5. 10.5.5 BUSINESS PERFORMANCE
  6. 10.5.6 BUSINESS SEGMENTS
  7. 10.5.7 GEOGRAPHIC SEGMENTS
  8. 10.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.5.9 PRIMARY MARKET COMPETITORS
11. 10.6 BECTON, DICKINSON AND COMPANY
12. 1. 10.6.1 COMPANY OVERVIEW
  2. 10.6.2 COMPANY SNAPSHOT
  3. 10.6.3 OPERATING BUSINESS SEGMENTS
  4. 10.6.4 PRODUCT PORTFOLIO
  5. 10.6.5 BUSINESS PERFORMANCE
  6. 10.6.6 BUSINESS SEGMENTS
  7. 10.6.7 GEOGRAPHIC SEGMENTS
  8. 10.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.6.9 PRIMARY MARKET COMPETITORS
13. 10.7 SYSMEX CORPORATION
14. 1. 10.7.1 COMPANY OVERVIEW
  2. 10.7.2 COMPANY SNAPSHOT
  3. 10.7.3 OPERATING BUSINESS SEGMENTS
  4. 10.7.4 PRODUCT PORTFOLIO
  5. 10.7.5 BUSINESS PERFORMANCE
  6. 10.7.6 BUSINESS SEGMENTS
  7. 10.7.7 GEOGRAPHIC SEGMENTS
  8. 10.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.7.9 PRIMARY MARKET COMPETITORS
15. 10.8 BIOMÉRIEUX
16. 1. 10.8.1 COMPANY OVERVIEW
  2. 10.8.2 COMPANY SNAPSHOT
  3. 10.8.3 OPERATING BUSINESS SEGMENTS
  4. 10.8.4 PRODUCT PORTFOLIO
  5. 10.8.5 BUSINESS PERFORMANCE
  6. 10.8.6 BUSINESS SEGMENTS
  7. 10.8.7 GEOGRAPHIC SEGMENTS
  8. 10.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.8.9 PRIMARY MARKET COMPETITORS
17. 10.9 BIO-RAD LABORATORIES
18. 1. 10.9.1 COMPANY OVERVIEW
  2. 10.9.2 COMPANY SNAPSHOT
  3. 10.9.3 OPERATING BUSINESS SEGMENTS
  4. 10.9.4 PRODUCT PORTFOLIO
  5. 10.9.5 BUSINESS PERFORMANCE
  6. 10.9.6 BUSINESS SEGMENTS
  7. 10.9.7 GEOGRAPHIC SEGMENTS
  8. 10.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.9.9 PRIMARY MARKET COMPETITORS
19. 10.10 QUIDELORTHO CORPORATION
20. 1. 10.10.1 COMPANY OVERVIEW
  2. 10.10.2 COMPANY SNAPSHOT
  3. 10.10.3 OPERATING BUSINESS SEGMENTS
  4. 10.10.4 PRODUCT PORTFOLIO
  5. 10.10.5 BUSINESS PERFORMANCE
  6. 10.10.6 BUSINESS SEGMENTS
  7. 10.10.7 GEOGRAPHIC SEGMENTS
  8. 10.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.10.9 PRIMARY MARKET COMPETITORS
21. 10.11 QIAGEN
22. 1. 10.11.1 COMPANY OVERVIEW
  2. 10.11.2 COMPANY SNAPSHOT
  3. 10.11.3 OPERATING BUSINESS SEGMENTS
  4. 10.11.4 PRODUCT PORTFOLIO
  5. 10.11.5 BUSINESS PERFORMANCE
  6. 10.11.6 BUSINESS SEGMENTS
  7. 10.11.7 GEOGRAPHIC SEGMENTS
  8. 10.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.11.9 PRIMARY MARKET COMPETITORS
23. 10.12 HOLOGIC, INC.
24. 1. 10.12.1 COMPANY OVERVIEW
  2. 10.12.2 COMPANY SNAPSHOT
  3. 10.12.3 OPERATING BUSINESS SEGMENTS
  4. 10.12.4 PRODUCT PORTFOLIO
  5. 10.12.5 BUSINESS PERFORMANCE
  6. 10.12.6 BUSINESS SEGMENTS
  7. 10.12.7 GEOGRAPHIC SEGMENTS
  8. 10.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.12.9 PRIMARY MARKET COMPETITORS
25. 10.13 DIASORIN S.P.A.
26. 1. 10.13.1 COMPANY OVERVIEW
  2. 10.13.2 COMPANY SNAPSHOT
  3. 10.13.3 OPERATING BUSINESS SEGMENTS
  4. 10.13.4 PRODUCT PORTFOLIO
  5. 10.13.5 BUSINESS PERFORMANCE
  6. 10.13.6 BUSINESS SEGMENTS
  7. 10.13.7 GEOGRAPHIC SEGMENTS
  8. 10.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.13.9 PRIMARY MARKET COMPETITORS
27. 10.14 GRIFOLS NORDIC AB
28. 1. 10.14.1 COMPANY OVERVIEW
  2. 10.14.2 COMPANY SNAPSHOT
  3. 10.14.3 OPERATING BUSINESS SEGMENTS
  4. 10.14.4 PRODUCT PORTFOLIO
  5. 10.14.5 BUSINESS PERFORMANCE
  6. 10.14.6 BUSINESS SEGMENTS
  7. 10.14.7 GEOGRAPHIC SEGMENTS
  8. 10.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.14.9 PRIMARY MARKET COMPETITORS
29. 10.15 AIDIAN OY
30. 1. 10.15.1 COMPANY OVERVIEW
  2. 10.15.2 COMPANY SNAPSHOT
  3. 10.15.3 OPERATING BUSINESS SEGMENTS
  4. 10.15.4 PRODUCT PORTFOLIO
  5. 10.15.5 BUSINESS PERFORMANCE
  6. 10.15.6 BUSINESS SEGMENTS
  7. 10.15.7 GEOGRAPHIC SEGMENTS
  8. 10.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.15.9 PRIMARY MARKET COMPETITORS

TABLE 1. FINLAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICES, 2024-2030, (MILLION USD)
TABLE 2. REAGENTS & CONSUMABLES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 3. CLINICAL CHEMISTRY REAGENTS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 4. IMMUNOASSAY REAGENTS (ELISA/CLIA), MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 5. MOLECULAR MASTER MIXES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 6. HEMATOLOGY CONTROLS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 7. INSTRUMENTS AND DEVICES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 8. CHEMISTRY ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 9. IMMUNOASSAY SYSTEMS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 10. MOLECULAR THERMOCYCLERS/SEQUENCERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 11. HEMATOLOGY ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 12. POC DEVICES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 13. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 14. LIS, DATA ANALYTICS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 15. CRO/TESTING SERVICES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 16. FINLAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (MILLION USD)
TABLE 17. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 18. METABOLITES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 19. ELECTROLYTES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 20. ENZYMES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 21. IMMUNOASSAYS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 22. ELISA/CLIA/CMIA, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 23. LATERAL-FLOW RAPID TESTS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 24. IMMUNOFLUORESCENCE, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 25. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 26. PCR, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 27. ISOTHERMAL NAAT, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 28. NGS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 29. IN-SITU HYBRIDIZATION, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 30. HEMATOLOGY & COAGULATION, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 31. CBC ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 32. COAGULATION PANELS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 33. MICROBIOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 34. CULTURE & SENSITIVITY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 35. MALDI-TOF, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 36. MOLECULAR ID, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 37. URINALYSIS AND BODY FLUIDS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 38. OTHER TECHNIQUES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 39. FINLAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY TESTING SITE/CHANNEL, 2024-2030, (MILLION USD)
TABLE 40. CENTRAL AND REFERENCE LABORATORIES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 41. HOSPITAL AND PHYSICIAN LABS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 42. POINT-OF-CARE AND RETAIL, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 43. HOME AND SELF-TESTING, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 44. FINLAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION/DISEASE AREA, 2024-2030, (MILLION USD)
TABLE 45. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 46. ONCOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 47. CARDIOVASCULAR HEALTH, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 48. ENDOCRINOLOGY AND DIABETES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 49. NEPHROLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 50. GENETIC AND PRENATAL TESTING, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 51. AUTOIMMUNE DISORDERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 52. DRUG MONITORING AND TOXICOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 53. BLOOD SCREENING AND TYPING, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 54. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 55. ROCHE DIAGNOSTICS OY: COMPANY SNAPSHOT
TABLE 56. ROCHE DIAGNOSTICS OY: OPERATING BUSINESS SEGMENTS
TABLE 57. ROCHE DIAGNOSTICS OY: PRODUCT PORTFOLIO
TABLE 58. ROCHE DIAGNOSTICS OY: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 59. ROCHE DIAGNOSTICS OY: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 60. ROCHE DIAGNOSTICS OY: KEY STRATERGY
TABLE 61. ABBOTT OY: COMPANY SNAPSHOT
TABLE 62. ABBOTT OY: OPERATING BUSINESS SEGMENTS
TABLE 63. ABBOTT OY: PRODUCT PORTFOLIO
TABLE 64. ABBOTT OY: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 65. ABBOTT OY: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 66. ABBOTT OY: KEY STRATERGY
TABLE 67. SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
TABLE 68. SIEMENS HEALTHINEERS: OPERATING BUSINESS SEGMENTS
TABLE 69. SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
TABLE 70. SIEMENS HEALTHINEERS: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 71. SIEMENS HEALTHINEERS: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 72. SIEMENS HEALTHINEERS: KEY STRATERGY
TABLE 73. DANAHER CORPORATION (BECKMAN COULTER): COMPANY SNAPSHOT
TABLE 74. DANAHER CORPORATION (BECKMAN COULTER): OPERATING BUSINESS SEGMENTS
TABLE 75. DANAHER CORPORATION (BECKMAN COULTER): PRODUCT PORTFOLIO
TABLE 76. DANAHER CORPORATION (BECKMAN COULTER): SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 77. DANAHER CORPORATION (BECKMAN COULTER): SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 78. DANAHER CORPORATION (BECKMAN COULTER): KEY STRATERGY
TABLE 79. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 80. THERMO FISHER SCIENTIFIC: OPERATING BUSINESS SEGMENTS
TABLE 81. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 82. THERMO FISHER SCIENTIFIC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 83. THERMO FISHER SCIENTIFIC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 84. THERMO FISHER SCIENTIFIC: KEY STRATERGY
TABLE 85. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 86. BECTON, DICKINSON AND COMPANY: OPERATING BUSINESS SEGMENTS
TABLE 87. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 88. BECTON, DICKINSON AND COMPANY: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 89. BECTON, DICKINSON AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 90. BECTON, DICKINSON AND COMPANY: KEY STRATERGY
TABLE 91. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 92. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 93. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 94. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 95. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 96. SYSMEX CORPORATION: KEY STRATERGY
TABLE 97. BIOMéRIEUX: COMPANY SNAPSHOT
TABLE 98. BIOMéRIEUX: OPERATING BUSINESS SEGMENTS
TABLE 99. BIOMéRIEUX: PRODUCT PORTFOLIO
TABLE 100. BIOMéRIEUX: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 101. BIOMéRIEUX: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 102. BIOMéRIEUX: KEY STRATERGY
TABLE 103. BIO-RAD LABORATORIES: COMPANY SNAPSHOT
TABLE 104. BIO-RAD LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 105. BIO-RAD LABORATORIES: PRODUCT PORTFOLIO
TABLE 106. BIO-RAD LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 107. BIO-RAD LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 108. BIO-RAD LABORATORIES: KEY STRATERGY
TABLE 109. QUIDELORTHO CORPORATION: COMPANY SNAPSHOT
TABLE 110. QUIDELORTHO CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 111. QUIDELORTHO CORPORATION: PRODUCT PORTFOLIO
TABLE 112. QUIDELORTHO CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 113. QUIDELORTHO CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 114. QUIDELORTHO CORPORATION: KEY STRATERGY
TABLE 115. QIAGEN: COMPANY SNAPSHOT
TABLE 116. QIAGEN: OPERATING BUSINESS SEGMENTS
TABLE 117. QIAGEN: PRODUCT PORTFOLIO
TABLE 118. QIAGEN: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 119. QIAGEN: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 120. QIAGEN: KEY STRATERGY
TABLE 121. HOLOGIC, INC.: COMPANY SNAPSHOT
TABLE 122. HOLOGIC, INC.: OPERATING BUSINESS SEGMENTS
TABLE 123. HOLOGIC, INC.: PRODUCT PORTFOLIO
TABLE 124. HOLOGIC, INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 125. HOLOGIC, INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 126. HOLOGIC, INC.: KEY STRATERGY
TABLE 127. DIASORIN S.P.A.: COMPANY SNAPSHOT
TABLE 128. DIASORIN S.P.A.: OPERATING BUSINESS SEGMENTS
TABLE 129. DIASORIN S.P.A.: PRODUCT PORTFOLIO
TABLE 130. DIASORIN S.P.A.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 131. DIASORIN S.P.A.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 132. DIASORIN S.P.A.: KEY STRATERGY
TABLE 133. GRIFOLS NORDIC AB: COMPANY SNAPSHOT
TABLE 134. GRIFOLS NORDIC AB: OPERATING BUSINESS SEGMENTS
TABLE 135. GRIFOLS NORDIC AB: PRODUCT PORTFOLIO
TABLE 136. GRIFOLS NORDIC AB: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 137. GRIFOLS NORDIC AB: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 138. GRIFOLS NORDIC AB: KEY STRATERGY
TABLE 139. AIDIAN OY: COMPANY SNAPSHOT
TABLE 140. AIDIAN OY: OPERATING BUSINESS SEGMENTS
TABLE 141. AIDIAN OY: PRODUCT PORTFOLIO
TABLE 142. AIDIAN OY: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 143. AIDIAN OY: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 144. AIDIAN OY: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. FINLAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICES, 2024-2030, (MILLION USD)
FIGURE 7. REAGENTS & CONSUMABLES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 8. CLINICAL CHEMISTRY REAGENTS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 9. IMMUNOASSAY REAGENTS (ELISA/CLIA), MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 10. MOLECULAR MASTER MIXES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 11. HEMATOLOGY CONTROLS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 12. INSTRUMENTS AND DEVICES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 13. CHEMISTRY ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 14. IMMUNOASSAY SYSTEMS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 15. MOLECULAR THERMOCYCLERS/SEQUENCERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 16. HEMATOLOGY ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 17. POC DEVICES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 18. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 19. LIS, DATA ANALYTICS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 20. CRO/TESTING SERVICES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 21. FINLAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (MILLION USD)
FIGURE 22. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 23. METABOLITES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 24. ELECTROLYTES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 25. ENZYMES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 26. IMMUNOASSAYS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 27. ELISA/CLIA/CMIA, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 28. LATERAL-FLOW RAPID TESTS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 29. IMMUNOFLUORESCENCE, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 30. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 31. PCR, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 32. ISOTHERMAL NAAT, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 33. NGS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 34. IN-SITU HYBRIDIZATION, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 35. HEMATOLOGY & COAGULATION, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 36. CBC ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 37. COAGULATION PANELS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 38. MICROBIOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 39. CULTURE & SENSITIVITY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 40. MALDI-TOF, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 41. MOLECULAR ID, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 42. URINALYSIS AND BODY FLUIDS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 43. OTHER TECHNIQUES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 44. FINLAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY TESTING SITE/CHANNEL, 2024-2030, (MILLION USD)
FIGURE 45. CENTRAL AND REFERENCE LABORATORIES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 46. HOSPITAL AND PHYSICIAN LABS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 47. POINT-OF-CARE AND RETAIL, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 48. HOME AND SELF-TESTING, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 49. FINLAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION/DISEASE AREA, 2024-2030, (MILLION USD)
FIGURE 50. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 51. ONCOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 52. CARDIOVASCULAR HEALTH, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 53. ENDOCRINOLOGY AND DIABETES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 54. NEPHROLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 55. GENETIC AND PRENATAL TESTING, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 56. AUTOIMMUNE DISORDERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 57. DRUG MONITORING AND TOXICOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 58. BLOOD SCREENING AND TYPING, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 59. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 60. ROCHE DIAGNOSTICS OY: NET SALES, (2022-2024)
FIGURE 61. ROCHE DIAGNOSTICS OY: PRIMARY MARKET COMPETITORS
FIGURE 62. ABBOTT OY: NET SALES, (2022-2024)
FIGURE 63. ABBOTT OY: PRIMARY MARKET COMPETITORS
FIGURE 64. SIEMENS HEALTHINEERS: NET SALES, (2022-2024)
FIGURE 65. SIEMENS HEALTHINEERS: PRIMARY MARKET COMPETITORS
FIGURE 66. DANAHER CORPORATION (BECKMAN COULTER): NET SALES, (2022-2024)
FIGURE 67. DANAHER CORPORATION (BECKMAN COULTER): PRIMARY MARKET COMPETITORS
FIGURE 68. THERMO FISHER SCIENTIFIC: NET SALES, (2022-2024)
FIGURE 69. THERMO FISHER SCIENTIFIC: PRIMARY MARKET COMPETITORS
FIGURE 70. BECTON, DICKINSON AND COMPANY: NET SALES, (2022-2024)
FIGURE 71. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS
FIGURE 72. SYSMEX CORPORATION: NET SALES, (2022-2024)
FIGURE 73. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 74. BIOMéRIEUX: NET SALES, (2022-2024)
FIGURE 75. BIOMéRIEUX: PRIMARY MARKET COMPETITORS
FIGURE 76. BIO-RAD LABORATORIES: NET SALES, (2022-2024)
FIGURE 77. BIO-RAD LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 78. QUIDELORTHO CORPORATION: NET SALES, (2022-2024)
FIGURE 79. QUIDELORTHO CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 80. QIAGEN: NET SALES, (2022-2024)
FIGURE 81. QIAGEN: PRIMARY MARKET COMPETITORS
FIGURE 82. HOLOGIC, INC.: NET SALES, (2022-2024)
FIGURE 83. HOLOGIC, INC.: PRIMARY MARKET COMPETITORS
FIGURE 84. DIASORIN S.P.A.: NET SALES, (2022-2024)
FIGURE 85. DIASORIN S.P.A.: PRIMARY MARKET COMPETITORS
FIGURE 86. GRIFOLS NORDIC AB: NET SALES, (2022-2024)
FIGURE 87. GRIFOLS NORDIC AB: PRIMARY MARKET COMPETITORS
FIGURE 88. AIDIAN OY: NET SALES, (2022-2024)
FIGURE 89. AIDIAN OY: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

The Finland in-vitro diagnostics market is estimated to reach USD 686.92 million by 2030.

The key players in the Finland in-vitro diagnostics market include Roche Diagnostics Oy, Abbott Oy, Siemens Healthineers, Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific, Becton, Dickinson and Company, Sysmex Corporation, bioMérieux, Bio-Rad Laboratories, QuidelOrtho Corporation, Qiagen, Hologic, Inc., Diasorin S.p.A., Grifols Nordic AB, Aidian Oy, and others.

The Finland in-vitro diagnostics market was estimate to reach USD 440.38 million in 2023.

High costs associated with research, development, and regulatory approval are significant factors restraining the market growth.

Introduction of Point-of-Care Testing Solutions creates opportunities for the in-vitro diagnostics in the coming future.

Download Free Sample

Phone Number *

Please enter Country Code and Phone No

Yes, I have read the Privacy Policy

Multi User

$2,575

Single User

$1,575

Enterprise

$3,875

Datapack

$1,975

Download Sample

Inquire Before Buying

Speak to Our Analyst

Share with Peers

About the Reviewer

Supradip Baul is the CEO and Founder of Next Move Strategy Consulting, driving the firm’s mission to provide data-driven insights and strategic intelligence. With extensive experience in market research and consulting, he has helped global organizations make informed decisions and achieve sustainable growth.

Request Sample

Phone Number *

Please enter Phone No

Please Select Country